PerkinElmer

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. With a global network and localized agility, the company serves a diverse range of organizations from pharmaceutical and biotech to clinical labs, academia, and governments. It is headquartered in Waltham, MA.

PerkinElmer's (PKI) Q3 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.

PerkinElmer (PKI) Q3 Earnings Beat Estimates, Revenues Miss

PerkinElmer's (PKI) CEO Rob Friel on Q3 2019 Results - Earnings Call Transcript

PerkinElmer (PKI) delivered earnings and revenue surprises of 4.95% and -2.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

PerkinElmer (PKI) Tops Q3 Earnings Estimates

Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q3 earnings. However, forex is likely to have been a dampener.

PerkinElmer (PKI) to Report Q3 Earnings: What's in Store?

PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PerkinElmer (PKI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock?

Why Is PerkinElmer (PKI) Down 8.4% Since Last Earnings Report?

Higher revenues and growth in Diagnostics segment benefit PerkinElmer's (PKI) Q2 earnings. However, forex remains a woe.

PerkinElmer (PKI) Q2 Earnings and Revenues Miss Estimates

PerkinElmer, Inc. (PKI) CEO Rob Friel on Q2 2019 Results - Earnings Call Transcript

PerkinElmer (PKI) delivered earnings and revenue surprises of -0.99% and -1.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

PerkinElmer (PKI) Misses Q2 Earnings and Revenue Estimates

Top-line growth and robust performance at Diagnostics segment are likely to aid PerkinElmer's (PKI) Q2 earnings. However, forex is likely to be a dampener.

What's in the Offing for PerkinElmer's (PKI) Earnings in Q2?

PerkinElmer (PKI) raises earnings per share guidance for 2019.

Here's Why You Should Hold PerkinElmer (PKI) Stock for Now

PerkinElmer (PKI) Down 9.2% Since Last Earnings Report: Can It Rebound?

PerkinElmer's (PKI) Q1 earnings gain from top-line growth, solid show by Diagnostics segment and strong margins. However, negative currency movement remains a headwind.

PerkinElmer (PKI) Beats on Q1 Earnings, Hikes '19 Guidance

PerkinElmer, Inc. (PKI) CEO Rob Friel on Q1 2019 Results - Earnings Call Transcript

Strength in PerkinElmer's (PKI) core Diagnostics business is expected to drive Q1 results amid foreign exchange woes.

Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q1 Earnings?

PerkinElmer (PKI) has been gaining investor confidence on consistently positive results.

News for PerkinElmer Stock (PKI)